PL3292135T3 - Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego - Google Patents

Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego

Info

Publication number
PL3292135T3
PL3292135T3 PL16724321.1T PL16724321T PL3292135T3 PL 3292135 T3 PL3292135 T3 PL 3292135T3 PL 16724321 T PL16724321 T PL 16724321T PL 3292135 T3 PL3292135 T3 PL 3292135T3
Authority
PL
Poland
Prior art keywords
polypeptide
barrier function
intestinal barrier
metabolic status
immune signalling
Prior art date
Application number
PL16724321.1T
Other languages
English (en)
Inventor
Clara BELZER
Willem Meindert De Vos
Patrice Daniel Cani
Original Assignee
Wageningen Universiteit
Université Catholique de Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wageningen Universiteit, Université Catholique de Louvain filed Critical Wageningen Universiteit
Publication of PL3292135T3 publication Critical patent/PL3292135T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL16724321.1T 2015-05-06 2016-05-04 Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego PL3292135T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166598 2015-05-06
PCT/EP2016/060033 WO2016177797A1 (en) 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Publications (1)

Publication Number Publication Date
PL3292135T3 true PL3292135T3 (pl) 2023-01-02

Family

ID=74184294

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16724321.1T PL3292135T3 (pl) 2015-05-06 2016-05-04 Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego

Country Status (17)

Country Link
US (2) US10738089B2 (pl)
EP (1) EP3292135B1 (pl)
JP (1) JP6894382B2 (pl)
KR (1) KR20180011130A (pl)
CN (1) CN107980043B (pl)
AU (2) AU2016257315A1 (pl)
BR (1) BR112017023751A2 (pl)
CA (1) CA2984985A1 (pl)
DK (1) DK3292135T3 (pl)
EA (1) EA201700507A1 (pl)
ES (1) ES2934138T3 (pl)
HK (1) HK1252412A1 (pl)
IL (1) IL255405B (pl)
MX (1) MX2017014111A (pl)
NZ (1) NZ737765A (pl)
PL (1) PL3292135T3 (pl)
WO (1) WO2016177797A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
KR20180011130A (ko) 2015-05-06 2018-01-31 바게닝겐 유니버시테이트 면역 신호전달 초래 및/또는 창자 장벽 기능에 영향 및/또는 대사 상태를 조절하기 위한 폴리펩티드의 용도
MX2018002990A (es) * 2015-09-10 2018-06-08 Univ Catholique Louvain Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
US11931400B2 (en) 2017-03-07 2024-03-19 Psomagen, Inc. Therapeutic and diagnostics compositions targeting toll-like receptors and methods thereof
US20200246488A1 (en) * 2017-07-17 2020-08-06 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel diseases
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
WO2020076043A1 (ko) * 2018-10-08 2020-04-16 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
KR102197180B1 (ko) * 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN110079474B (zh) * 2019-04-12 2022-11-25 沈阳药科大学 一种高密度培养艾克曼嗜黏蛋白菌的方法
KR102263030B1 (ko) * 2019-05-07 2021-06-10 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
JP7417321B2 (ja) * 2019-09-25 2024-01-18 ヘルスバイオミー 癌治療のための絶対嫌気性人体腸内微生物及びその用途
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN110950937B (zh) * 2019-11-25 2021-05-04 安徽大学 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用
EP4087859A4 (en) * 2020-01-10 2024-02-14 National Taipei University of Technology PEPTIDE INTERACTING WITH THE TOLL 2 RECEPTOR AND COMPOSITION COMPRISING SAME
KR102671044B1 (ko) * 2020-03-25 2024-05-31 한국생명공학연구원 아커만시아 뮤시니필라 유래의 tars 또는 이의 단편 및 이의 용도
US20210322492A1 (en) * 2020-04-16 2021-10-21 Amucin Oy Ltd Probiotic strains and uses thereof
CN111690044B (zh) * 2020-05-06 2022-03-01 中南大学湘雅二医院 Amuc1100蛋白的用途
CN115996943A (zh) 2020-07-01 2023-04-21 瓦赫宁根大学 用于影响免疫信号传导和/或影响肠屏障功能和/或调节代谢状态的Amuc-1100多肽变体
KR20220061018A (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN113413466B (zh) * 2020-12-15 2022-08-19 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法
CN115364198A (zh) * 2022-08-23 2022-11-22 广州康泽医疗科技有限公司 膜蛋白Amuc_1100在促进前脂肪细胞脂解和棕色化中的应用
CN116059254A (zh) * 2023-02-27 2023-05-05 广州知易生物科技有限公司 嗜黏蛋白阿克曼氏菌在制备用于改善和治疗多发性硬化症药物中的应用
CN117304264B (zh) * 2023-11-27 2024-02-06 中国科学院烟台海岸带研究所 一种具有肠屏障保护功能的五肽rp5及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
DE60229508D1 (de) * 2001-02-28 2008-12-04 Nat Inst Of Advanced Ind Scien Drosophila-stamm, der in diesen übertragene(s) bradeion-gen(e) enthält
CA2511775A1 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1,-a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
US20050180962A1 (en) 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
US20050163764A1 (en) * 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US7812121B2 (en) 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
AU2010247469B2 (en) 2009-05-11 2014-12-18 Société des Produits Nestlé S.A. Lactobacillus johnsonii La1 NCC533 (CNCM I-1225) and immune disorders
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms
US9104670B2 (en) 2010-07-21 2015-08-11 Apple Inc. Customized search or acquisition of digital media assets
ES2616236T3 (es) 2010-10-20 2017-06-12 Philips Lighting Holding B.V. Aparatos de desagregación
EP2449887B1 (en) 2010-11-05 2016-01-06 Nestec S.A. Method for preparing pet food containing probiotic micro-organisms
EP2449891A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
CN110201003A (zh) 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
KR20180011130A (ko) 2015-05-06 2018-01-31 바게닝겐 유니버시테이트 면역 신호전달 초래 및/또는 창자 장벽 기능에 영향 및/또는 대사 상태를 조절하기 위한 폴리펩티드의 용도
MX2018002990A (es) 2015-09-10 2018-06-08 Univ Catholique Louvain Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
US11071626B2 (en) 2018-03-16 2021-07-27 W. L. Gore & Associates, Inc. Diametric expansion features for prosthetic valves

Also Published As

Publication number Publication date
AU2020267210B2 (en) 2023-10-12
AU2020267210A1 (en) 2020-12-17
CN107980043A (zh) 2018-05-01
JP6894382B2 (ja) 2021-06-30
US20210147489A1 (en) 2021-05-20
KR20180011130A (ko) 2018-01-31
EP3292135A1 (en) 2018-03-14
US11466057B2 (en) 2022-10-11
US10738089B2 (en) 2020-08-11
MX2017014111A (es) 2018-02-26
WO2016177797A1 (en) 2016-11-10
BR112017023751A2 (pt) 2018-07-31
US20180265554A1 (en) 2018-09-20
ES2934138T3 (es) 2023-02-17
CA2984985A1 (en) 2016-11-10
HK1252412A1 (zh) 2019-05-24
CN107980043B (zh) 2021-09-24
EA201700507A1 (ru) 2018-05-31
IL255405A0 (en) 2017-12-31
AU2016257315A1 (en) 2017-11-23
JP2018515502A (ja) 2018-06-14
NZ737765A (en) 2024-08-30
IL255405B (en) 2022-01-01
EP3292135B1 (en) 2022-09-21
DK3292135T3 (da) 2022-10-31

Similar Documents

Publication Publication Date Title
HK1252412A1 (zh) 多肽用於作用於免疫信號轉導和/或影響腸屏障功能和/或調節代謝狀態的用途
PT3292135T (pt) Uso de um polipéptido para efetuar a sinalização imunitária e/ou afetar a função de barreira intestinal e/ou regular o estado metabólico
IL252812A0 (en) Pyrin polypeptide and immune modulation
EP3569516C0 (de) Dosendeckel
IL250571B (en) coupling and gasket
GB2561542B (en) Ampoule closure
PL3687634T3 (pl) Maska pełnotwarzowa
IL247551B (en) A peptide drug in the form of a dry powder
SG11202001400YA (en) Closure
ZA201704991B (en) Container closure systems
ZA201800643B (en) Closure system
LT3225283T (lt) Priešgaisrinė užtvara
ZA201905760B (en) Tamper evident closure
AP00995S1 (en) Security seal
GB201708099D0 (en) Closure
AU201711445S (en) Closure
PL3163132T3 (pl) Urządzenie do uszczelniania oraz system do nakładania zawierający takie urządzenie
GB201522995D0 (en) A closure system
GB2537810B (en) Flexible seal
GB201506785D0 (en) Face mask and face seal component
GB201504273D0 (en) Overhood seal and use thereof
GB201421519D0 (en) A flood barrier system and a barrier thereof
GB201405864D0 (en) Waterproof closure system